Myocardial reperfusion injury: Looking beyond primary PCI

European Heart Journal

Volumn 34, Issue 23, 2013, Pages 1714-1724

  Fröhlich, Georg M ^a   Meier, Pascal ^a   White, Steven K ^a,b   Yellon, Derek M ^b   Hausenloy, Derek J ^a,b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b Hatter Cardiovascular Institute   (United Kingdom)

Author keywords

Cardioprotection; Myocardial reperfusion injury; Primary percutaneous coronary intervention; ST elevation myocardial infarction

Indexed keywords

CALCIUM; CANGRELOR; CLOPIDOGREL; CYCLOSPORIN A; EXENDIN 4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID PEROXIDE; NITRATE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RECOMBINANT SOMATOMEDIN C; VASODILATOR AGENT;

ANGINA PECTORIS; BLOOD VESSEL OCCLUSION; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CARDIOVASCULAR MAGNETIC RESONANCE; CELL PH; HEART INFARCTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART MUSCLE CELL; HEART MUSCLE REPERFUSION; HEART MUSCLE REVASCULARIZATION; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERBARIC OXYGEN; INDUCED HYPOTHERMIA; INTRAMYOCARDIAL BLEEDING; ISCHEMIC HEART DISEASE; MICROVASCULAR OBSTRUCTION; MITOCHONDRIAL PERMEABILITY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION INJURY; REVIEW; SARCOPLASMIC RETICULUM; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STUNNED HEART MUSCLE; THROMBOCYTE AGGREGATION;

CARDIOPROTECTION; MYOCARDIAL REPERFUSION INJURY; PRIMARY PERCUTANEOUS CORONARY INTERVENTION; ST-ELEVATION MYOCARDIAL INFARCTION;

ANIMALS; ARRHYTHMIAS, CARDIAC; ATRIAL NATRIURETIC FACTOR; BLOOD GLUCOSE; CALCIUM; CARDIOTONIC AGENTS; CELL DEATH; CORONARY OCCLUSION; DISEASE MODELS, ANIMAL; HEMORRHAGE; HUMANS; HYDROGEN-ION CONCENTRATION; HYPERBARIC OXYGENATION; HYPOTHERMIA, INDUCED; ISCHEMIC POSTCONDITIONING; MICROVESSELS; MITOCHONDRIA, HEART; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDITIS; MYOCYTES, CARDIAC; NITRIC OXIDE; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION;

EID: 84879090443     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht090     Document Type: Review

References (107)

1. Ginks WR, Sybers HD, Maroko PR, Covell JW, Sobel BE, Ross J Jr. Coronary artery reperfusion. II. Reduction of myocardial infarct size at 1 week after the coronary occlusion. J Clin Invest 1972;51:2717-2723.
2. Mandelzweig L, Battler A, Boyko V, Bueno H, Danchin N, Filippatos G, Gitt A, Hasdai D, Hasin Y, Marrugat J, Van de Werf F, Wallentin L, Behar S. The second Euro Heart Survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J 2006;27:2285-2293.
3. Piper HM, Garcia-Dorado D, Ovize M. A fresh look at reperfusion injury. Cardiovasc Res 1998;38:291-300.
4. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357: 1121-1135.
5. Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, Di MC, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't HA, Widimsky P, Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-2619.
6. Manning AS, Hearse DJ. Reperfusion-induced arrhythmias: mechanisms and prevention. J Mol Cell Cardiol 1984;16:497-518.
7. Kukreja RC, Janin Y. Reperfusion injury: basic concepts and protection strategies. J Thromb Thrombolysis 1997;4:7-24.
8. Bolli R, Marban E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev 1999;79:609-634.
9. Krug A, Du Mesnil dR, Korb G. Blood supply of the myocardium after temporary coronary occlusion. Circ Res 1966;19:57-62.
10. Heusch G, Kleinbongard P, Bose D, Levkau B, Haude M, Schulz R, Erbel R. Coronary microembolization: from bedside to bench and back to bedside. Circulation 2009;120:1822-1836.
11. Kleinbongard P, Bose D, Baars T, Mohlenkamp S, Konorza T, Schoner S, Elter-Schulz M, Eggebrecht H, Degen H, Haude M, Levkau B, Schulz R, Erbel R, Heusch G. Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary bypass grafts and its pharmacological attenuation. Circ Res 2011;108:344-352.
12. Heusch G. Reprint of: the paradox of alpha-adrenergic coronary vasoconstriction revisited. J Mol Cell Cardiol 2012;52:832-839.
13. Ito H, Maruyama A, Iwakura K, Takiuchi S, Masuyama T, Hori M, Higashino Y, Fujii K, Minamino T. Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996;93:223-228.
14. Schofer J, Montz R, Mathey DG. Scintigraphic evidence of the 'no reflow' phenomenon in human beings after coronary thrombolysis. J Am Coll Cardiol 1985; 5:593-598.
15. Bogaert J, Kalantzi M, Rademakers FE, Dymarkowski S, Janssens S. Determinants and impact of microvascular obstruction in successfully reperfused ST-segment elevation myocardial infarction. Assessment by magnetic resonance imaging. Eur Radiol 2007;17:2572-2580.
16. Ganame J, Messalli G, Dymarkowski S, Rademakers FE, Desmet W, Van De WF, Bogaert J. Impact of myocardial haemorrhage on left ventricular function and remodelling in patients with reperfused acute myocardial infarction. Eur Heart J 2009;30:1440-1449.
17. Jennings R, Sommers H, Smyth G, lack H, Linn H. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol 1960;70:68-78.
18. Kloner RA. Does reperfusion injury exist in humans? J Am Coll Cardiol 1993;21: 537-545.
19. Crompton M, Costi A. Kinetic evidence for a heart mitochondrial pore activated by Ca2+, inorganic phosphate and oxidative stress. A potential mechanism for mitochondrial dysfunction during cellular Ca2+ overload. Eur J Biochem 1988; 178:489-501.
20. Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 1995;307:93-98.
21. Hausenloy DJ, Yellon DM. The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol 2003;35:339-341.
22. Heusch G, Boengler K, Schulz R. Inhibition of mitochondrial permeability transition pore opening: the Holy Grail of cardioprotection. Basic Res Cardiol 2010;105:151-154.
23. Hausenloy DJ, Duchen MR, Yellon DM. Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc Res 2003;60:617-625.
24. Argaud L, Gateau-Roesch O, Muntean D, Chalabreysse L, Loufouat J, Robert D, Ovize M. Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury. J Mol Cell Cardiol 2005;38:367-374.
25. Skyschally A, Schulz R, Heusch G. Cyclosporine A at reperfusion reduces infarct size in pigs. Cardiovasc Drugs Ther 2010;24:85-87.
26. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, Brunskill EW, Sayen MR, Gottlieb RA, Dorn GW, Robbins J, Molkentin JD. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 2005;434:658-662.
27. Shen AC, Jennings RB. Myocardial calcium and magnesium in acute ischemic injury. Am J Pathol 1972;67:417-440.
28. Klein HH, Pich S, Lindert S, Nebendahl K, Warneke G, Kreuzer H. Treatment of reperfusion injury with intracoronary calcium channel antagonists and reduced coronary free calcium concentration in regionally ischemic, reperfused porcine hearts. J Am Coll Cardiol 1989;13:1395-1401.
29. Carry MM, Mrak RE, Murphy ML, Peng CF, Straub KD, Fody EP. Reperfusion injury in ischemic myocardium: protective effects of ruthenium red and of nitroprusside. Am J Cardiovasc Pathol 1989;2:335-344.
30. Boden WE, van Gilst WH, Scheldewaert RG, Starkey IR, Carlier MF, Julian DG, Whitehead A, Bertrand ME, Col JJ, Pedersen OL, Lie KI, Santoni JP, Fox KM. Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomised placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT). Lancet 2000;355:1751-1756.
31. Bar FW, Tzivoni D, Dirksen MT, Fernandez-Ortiz A, Heyndrickx GR, Brachmann J, Reiber JH, Avasthy N, Tatsuno J, Davies M, Hibberd MG, Krucoff MW. Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-Elevation Myocardial Infarction: the randomized multicentre CASTEMI study. Eur Heart J 2006;27:2516-2523.
32. Zeymer U, Suryapranata H, Monassier JP, Opolski G, Davies J, Rasmanis G, Linssen G, Tebbe U, Schroder R, Tiemann R, Machnig T, Neuhaus KL. The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J Am Coll Cardiol 2001;38:1644-1650.
33. De SD, Raffaello A, Teardo E, Szabo I, Rizzuto R. A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporter. Nature 2011;476: 336-340.
34. Zweier JL. Measurement of superoxide-derived free radicals in the reperfused heart. Evidence for a free radical mechanism of reperfusion injury. J Biol Chem 1988;263:1353-1357.
35. Downey JM. Free radicals and their involvement during long-term myocardial ischemia and reperfusion. Annu Rev Physiol 1990;52:487-504.
36. Effect of 48-h intravenous trimetazidine on short-and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; a double-blind, placebo-controlled, randomized trial. The EMIP-FR Group. European Myocardial Infarction Project-Free Radicals. Eur Heart J 2000;21:1537-1546.
37. Zweier JL, Talukder MA. The role of oxidants and free radicals in reperfusion injury. Cardiovasc Res 2006;70:181-190.
38. Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, Seguchi O, Myoishi M, Minamino T, Ohara T, Nagai Y, Nanto S, Watanabe K, Fukuzawa S, Hirayama A, Nakamura N, Kimura K, Fujii K, Ishihara M, Saito Y, Tomoike H, Kitamura S. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 2007;370:1483-1493.
39. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 2004;61:481-497.
40. Litt MR, Jeremy RW, Weisman HF, Winkelstein JA, Becker LC. Neutrophil depletion limited to reperfusion reduces myocardial infarct size after 90 minutes of ischemia. Evidence for neutrophil-mediated reperfusion injury. Circulation 1989;80:1816-1827.
41. Hayward R, Campbell B, Shin YK, Scalia R, Lefer AM. Recombinant soluble Pselectin glycoprotein ligand-1 protects against myocardial ischemic reperfusion injury in cats. Cardiovasc Res 1999;41:65-76.
42. Ma XL, Tsao PS, Lefer AM. Antibody to CD-18 exerts endothelial and cardiac protective effects in myocardial ischemia and reperfusion. J Clin Invest 1991;88: 1237-1243.
43. Zhao ZQ, Lefer DJ, Sato H, Hart KK, Jefforda PR, Vinten-Johansen J. Monoclonal antibody to ICAM-1 preserves postischemic blood flow and reduces infarct size after ischemia-reperfusion in rabbit. J Leukoc Biol 1997;62:292-300.
44. Ross AM, Gibbons RJ, Stone GW, Kloner RA, Alexander RW. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005;45:1775-1780.
45. Armstrong PW, Granger CB, Adams PX, Hamm C, Holmes D Jr, O'Neill WW, Todaro TG, Vahanian A, Van De WF. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 2007;297:43-51.
46. Atar D, Petzelbauer P, Schwitter J, Huber K, Rensing B, Kasprzak JD, Butter C, Grip L, Hansen PR, Suselbeck T, Clemmensen PM, Marin-Galiano M, Geudelin B, Buser PT. Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J Am Coll Cardiol 2009;53:720-729.
47. Ludman A, Venugopal V, Yellon DM, Hausenloy DJ. Statins and cardioprotection- more than just lipid lowering? Pharmacol Ther 2009;122:30-43.
48. Heusch G. Adenosine and maximum coronary vasodilation in humans: myth and misconceptions in the assessment of coronary reserve. Basic Res Cardiol 2010; 105:1-5.
49. Lemasters JJ, Bond JM, Chacon E, Harper IS, Kaplan SH, Ohata H, Trollinger DR, Herman B, Cascio WE. The pH paradox in ischemia-reperfusion injury to cardiac myocytes. EXS 1996;76:99-114.
50. Kim JS, Jin Y, Lemasters JJ. Reactive oxygen species, but not Ca2+ overloading, trigger pH-and mitochondrial permeability transition-dependent death of adult rat myocytes after ischemia-reperfusion. Am J Physiol Heart Circ Physiol 2006;290: H2024-H2034.
51. Fujita M, Asanuma H, Hirata A, Wakeno M, Takahama H, Sasaki H, Kim J, Takashima S, Tsukamoto O, Minamino T, Shinozaki Y, Tomoike H, Hori M, Kitakaze M. Prolonged transient acidosis during early reperfusion contributes to the cardioprotective effects of postconditioning. Am J Physiol Heart Circ Physiol 2007;292:H2004-H2008.
52. Cohen MV, Yang XM, Downey JM. The pH hypothesis of postconditioning: staccato reperfusion reintroduces oxygen and perpetuates myocardial acidosis. Circulation 2007;115:1895-1903.
53. Vander Heide RS, Altschuld RA, Lamka KG, Ganote CE. Modification of caffeine-induced injury in Ca2+-free perfused rat hearts. Relationship to the calcium paradox. Am J Pathol 1986;123:351-364.
54. Garcia-Dorado D, Ruiz-Meana M, Inserte J, Rodriguez-Sinovas A, Piper HM. Calcium-mediated cell death during myocardial reperfusion. Cardiovasc Res 2012;94:168-180.
55. Siegmund B, Klietz T, Schwartz P, Piper HM. Temporary contractile blockade prevents hypercontracture in anoxic-reoxygenated cardiomyocytes. Am J Physiol 1991;260:H426-H435.
56. Gao E, Boucher M, Chuprun JK, Zhou RH, Eckhart AD, Koch WJ. Darbepoetin alfa, a long-acting erythropoietin analog, offers novel and delayed cardioprotection for the ischemic heart. Am J Physiol Heart Circ Physiol 2007;293:H60-H68.
57. Doukas J, Wrasidlo W, Noronha G, Dneprovskaia E, Fine R, Weis S, Hood J, Demaria A, Soll R, Cheresh D. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc Natl Acad Sci USA 2006;103:19866-19871.
58. Roubille F, Franck-Miclo A, Covinhes A, Lafont C, Cransac F, Combes S, Vincent A, Fontanaud P, Sportouch-Dukhan C, Redt-Clouet C, Nargeot J, Piot C, Barrere-Lemaire S. Delayed postconditioning in the mouse heart in vivo. Circulation 2011;124:1330-1336.
59. Rochitte CE, Lima JA, Bluemke DA, Reeder SB, McVeigh ER, Furuta T, Becker LC, Melin JA. Magnitude and time course of microvascular obstruction and tissue injury after acute myocardial infarction. Circulation 1998;98: 1006-1014.
60. Ytrehus K, Liu Y, Tsuchida A, Miura T, Liu GS, Yang XM, Herbert D, Cohen MV, Downey JM. Rat and rabbit heart infarction: effects of anesthesia, perfusate, risk zone, and method of infarct sizing. Am J Physiol 1994;267:H2383-H2390.
61. Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L'Huillier I, Aupetit JF, Bonnefoy E, Finet G, Andre-Fouet X, Ovize M. Postconditioning the human heart. Circulation 2005;112:2143-2148.
62. Schwartz LL, Kloner RA, Arai AE, Baines CP, Bolli R, Braunwald E, Downey J, Gibbons RJ, Gottlieb RA, Heusch G, Jennings RB, Lefer DJ, Mentzer RM, Murphy E, Ovize M, Ping P, Przyklenk K, Sack MN, Vander Heide RS, Vinten-Johansen J, Yellon DM. New horizons in cardioprotection: recommendations from the 2010 national heart, lung, and blood institute workshop. Circulation 2011;124:1172-1179.
63. Bell R, Beeuwkes R, Botker HE, Davidson S, Downey J, Garcia-Dorado D, Hausenloy DJ, Heusch G, Ibanez B, Kitakaze M, Lecour S, Mentzer R, Miura T, Opie L, Ovize M, Ruiz-Meana M, Schulz R, Shannon R, Walker M, Vinten-Johansen J, Yellon D. Trials, tribulations and speculation! Report from the 7th Biennial Hatter Cardiovascular Institute Workshop. Basic Res Cardiol 2012;107:300.
64. Hausenloy DJ, Botker HE, Condorelli G, Ferdinandy P, Garcia-Dorado D, Heusch G, Lecour S, van Laake LW, Madonna R, Ruiz-Meana M, Schulz R, Sluijter JP, Yellon DM, Ovize M. Translating cardioprotection for patient benefit: Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res; doi: 10.1093/cvr/cvt004. Published online ahead of print 19 January 2013.
65. Heusch G. Cardioprotection: chances and challenges of its translation to the clinic. Lancet 2013;381:166-175.
66. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 2007;59:418-458.
67. Napoli C, Liguori A, Chiariello M, Di Ieso N, Condorelli M, Ambrosio G. Newonset angina preceding acute myocardial infarction is associated with improved contractile recovery after thrombolysis. Eur Heart J 1998;19:411-419.
68. Ambrosio G, Del PM, Tritto I, Agnelli G, Bentivoglio M, Zuchi C, Anderson FA, Gore JM, Lopez-Sendon J, Wyman A, Kennelly BM, Fox KA. Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: insights from 52,693 patients in the Global Registry of Acute Coronary Events. Eur Heart J 2010;31:430-438.
69. Kloner RA, Schwartz LL. State of the Science of Cardioprotection: Challenges and Opportunities-Proceedings of the 2010 NHLBI Workshop on Cardioprotection. J Cardiovasc Pharmacol Ther 2011;16:223-232.
70. Musiolik J, van CP, Skyschally A, Boengler K, Gres P, Schulz R, Heusch G. Reduction of infarct size by gentle reperfusion without activation of reperfusion injury salvage kinases in pigs. Cardiovasc Res 2010;85:110-117.
71. Heusch G, Kleinbongard P, Skyschally A, Levkau B, Schulz R, Erbel R. The coronary circulation in cardioprotection: more than just one confounder. Cardiovasc Res 2012;94:237-245.
72. Skyschally A, Walter B, Heusch G. Coronary microembolization during early reperfusion: infarct extension, but protection by ischaemic postconditioning. Eur Heart J; doi: 10.1093/eurheartj/ehs434. Published online ahead of print 13 December 2012.
73. Aletras AH, Tilak GS, Natanzon A, Hsu LY, Gonzalez FM, Hoyt RF Jr, Arai AE. Retrospective determination of the area at risk for reperfused acute myocardial infarction with T2-weighted cardiac magnetic resonance imaging: histopathological and displacement encoding with stimulated echoes (DENSE) functional validations. Circulation 2006;113:1865-1870.
74. Friedrich MG, Abdel-Aty H, Taylor A, Schulz-Menger J, Messroghli D, Dietz R. The salvaged area at risk in reperfused acute myocardial infarction as visualized by cardiovascular magnetic resonance. J Am Coll Cardiol 2008;51:1581-1587.
75. Thuny F, Lairez O, Roubille F, Mewton N, Rioufol G, Sportouch C, Sanchez I, Bergerot C, Thibault H, Cung TT, Finet G, Argaud L, Revel D, Derumeaux G, Bonnefoy-Cudraz E, Elbaz M, Piot C, Ovize M, Croisille P. Post-conditioning reduces infarct size and edema in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 2012;59:2175-2181.
76. Zhao ZQ, Corvera JS, Halkos ME, Kerendi F, Wang NP, Guyton RA, Vinten-Johansen J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003;285:H579-H588.
77. Okamoto F, Allen BS, Buckberg GD, Bugyi H, Leaf J. Reperfusion conditions: importance of ensuring gentle versus sudden reperfusion during relief of coronary occlusion. J Thorac Cardiovasc Surg 1986;92:613-620.
78. Heusch G. Postconditioning: old wine in a new bottle? J Am Coll Cardiol 2004;44: 1111-1112.
79. Heusch G. Reduction of infarct size by ischaemic post-conditioning in humans: fact or fiction? Eur Heart J 2012;33:13-15.
80. O'Neill WW, Martin JL, Dixon SR, Bartorelli AL, Trabattoni D, Oemrawsingh PV, Atsma DE, Chang M, Marquardt W, Oh JK, Krucoff MW, Gibbons RJ, Spears JR. Acute Myocardial Infarction with Hyperoxemic Therapy (AMIHOT): a prospective, randomized trial of intracoronary hyperoxemic reperfusion after percutaneous coronary intervention. J Am Coll Cardiol 2007;50:397-405.
81. Duncker DJ, Klassen CL, Ishibashi Y, Herrlinger SH, Pavek TJ, Bache RJ. Effect of temperature on myocardial infarction in swine. Am J Physiol 1996;270: H1189-H1199.
82. Hausenloy DJ, Yellon DM. Remote ischaemic preconditioning: underlying mechanisms and clinical application. Cardiovasc Res 2008;79:377-386.
83. Botker HE, Kharbanda R, Schmidt MR, Bottcher M, Kaltoft AK, Terkelsen CJ, Munk K, Andersen NH, Hansen TM, Trautner S, Lassen JF, Christiansen EH, Krusell LR, Kristensen SD, Thuesen L, Nielsen SS, Rehling M, Sorensen HT, Redington AN, Nielsen TT. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 2010;375: 727-734.
84. Redington KL, Disenhouse T, Strantzas SC, Gladstone R, Wei C, Tropak MB, Dai X, Manlhiot C, Li J, Redington AN. Remote cardioprotection by direct peripheral nerve stimulation and topical capsaicin is mediated by circulating humoral factors. Basic Res Cardiol 2012;107:1-10.
85. Yang XM, Philipp S, Downey JM, Cohen MV. Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts. Basic Res Cardiol 2006;101:311-318.
86. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, Angoulvant D, Macia C, Raczka F, Sportouch C, Gahide G, Finet G, Andre-Fouet X, Revel D, Kirkorian G, Monassier JP, Derumeaux G, Ovize M. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008;359:473-481.
87. Stuckey DJ, Carr CA, Camelliti P, Tyler DJ, Davies KE, Clarke K. In vivo MRI characterization of progressive cardiac dysfunction in the mdx mouse model of muscular dystrophy. PLoS One 2012;7:e28569.
88. Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P, Verlaan CW, Kerver M, Piek JJ, Doevendans PA, Pasterkamp G, Hoefer IE. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009;53:501-510.
89. Lonborg J, Vejlstrup N, Kelbaek H, Botker HE, Kim WY, Mathiasen AB, Jorgensen E, Helqvist S, Saunamaki K, Clemmensen P, Holmvang L, Thuesen L, Krusell LR, Jensen JS, Kober L, Treiman M, Holst JJ, Engstrom T. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012;33:1491-1499.
90. Lonborg J, Kelbaek H, Vejlstrup N, Botker HE, Kim WY, Holmvang L, Jorgensen E, Helqvist S, Saunamaki K, Terkelsen CJ, Schoos MM, Kober L, Clemmensen P, Treiman M, Engstrom T. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv 2012;5:288-295.
91. Opie LH. The glucose hypothesis: relation to acute myocardial ischemia. J Mol Cell Cardiol 1970;1:107-115.
92. Mehta SR, Yusuf S, Diaz R, Zhu J, Pais P, Xavier D, Paolasso E, Ahmed R, Xie C, Kazmi K, Tai J, Orlandini A, Pogue J, Liu L. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA 2005;293: 437-446.
93. Selker HP, Beshansky JR, Sheehan PR, Massaro JM, Griffith JL, D'Agostino RB, Ruthazer R, Atkins JM, Sayah AJ, Levy MK, Richards ME, Aufderheide TP, Braude DA, Pirrallo RG, Doyle DD, Frascone RJ, Kosiak DJ, Leaming JM, Van Gelder CM, Walter GP, Wayne MA, Woolard RH, Opie LH, Rackley CE, Apstein CS, Udelson JE. Out-of-hospital administration of intravenous glucose-insulin-potassium in patients with suspected acute coronary syndromes: the IMMEDIATE randomized controlled trial. JAMA 2012;307:1925-1933.
94. Ibanez B, Fuster V, Macaya C, Sanchez-Brunete V, Pizarro G, Lopez-Romero P, Mateos A, Jimenez-Borreguero J, Fernandez-Ortiz A, Sanz G, Fernandez-Friera L, Corral E, Barreiro MV, Ruiz-Mateos B, Goicolea J, Hernandez-Antolin R, Acebal C, Garcia-Rubira JC, Albarran A, Zamorano JL, Casado I, Valenciano J, Fernandez-Vazquez F, de la Torre JM, Perez de PA, Iglesias-Vazquez JA, Martinez-Tenorio P, Iniguez A. Study design for the 'effect of METOprolol in CARDioproteCtioN during an acute myocardial InfarCtion' (METOCARD-CNIC): a randomized, controlled parallel-group, observerblinded clinical trial of early pre-reperfusion metoprolol administration in ST-segment elevation myocardial infarction. Am Heart J 2012;164:473-480.
95. Yang XM, Liu Y, Cui L, Yang X, Liu Y, Tandon N, Kambayashi J, Downey JM, Cohen MV. Platelet P2Y12 blockers confer direct postconditioning-like protection in reperfused rabbit hearts. J Cardiovasc Pharmacol Ther; doi: 10.1177/1074248412467692. Published online ahead of print 10 December 2012.
96. Yang XM, Liu Y, Cui L, Yang X, Liu Y, Tandon N, Kambayashi J, Downey JM, Cohen MV. Two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts. Cardiovasc Drugs Ther 2013;27:109-115.
97. Roubille F, Lairez O, Mewton N, Rioufol G, Ranc S, Sanchez I, Cung TT, Elbaz M, Piot C, Ovize M. Cardioprotection by clopidogrel in acute ST-elevated myocardial infarction patients: a retrospective analysis. Basic Res Cardiol 2012;107:275.
98. Thibault H, Piot C, Staat P, Bontemps L, Sportouch C, Rioufol G, Cung TT, Bonnefoy E, Angoulvant D, Aupetit JF, Finet G, Andre-Fouet X, Macia JC, Raczka F, Rossi R, Itti R, Kirkorian G, Derumeaux G, Ovize M. Long-term benefit of postconditioning. Circulation 2008;117:1037-1044.
99. Lonborg J, Kelbaek H, Vejlstrup N, Jorgensen E, Helqvist S, Saunamaki K, Clemmensen P, Holmvang L, Treiman M, Jensen JS, Engstrom T. Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance. Circ Cardiovasc Interv 2010;3:34-41.
100. Sorensson P, Saleh N, Bouvier F, Bohm F, Settergren M, Caidahl K, Tornvall P, Arheden H, Ryden L, Pernow J. Effect of postconditioning on infarct size in patients with ST elevation myocardial infarction. Heart 2010;96: 1710-1715.
101. Tarantini G, Favaretto E, Marra MP, Frigo AC, Napodano M, Cacciavillani L, Giovagnoni A, Renda P, De BV, Plebani M, Mion M, Zaninotto M, Isabella G, Bilato C, Iliceto S. Postconditioning during coronary angioplasty in acute myocardial infarction: the POST-AMI trial. Int J Cardiol 2012;162:33-38.
102. Hyen-Cheol et al. 2012. Effects of postconditioning on myocardial reperfusion (POST). www.ClinicalTrials.gov Identifier: NCT00942500.
103. Stone GW, Martin JL, de Boer MJ, Margheri M, Bramucci E, Blankenship JC, Metzger DC, Gibbons RJ, Lindsay BS, Weiner BH, Lansky AJ, Krucoff MW, Fahy M, Boscardin WJ. Effect of supersaturated oxygen delivery on infarct size after percutaneous coronary intervention in acute myocardial infarction. Circ Cardiovasc Interv 2009;2:366-375.
104. Gotberg M, Olivecrona GK, Koul S, Carlsson M, Engblom H, Ugander M, van der Pals J, Algotsson L, Arheden H, Erlinge D. A pilot study of rapid cooling by cold saline and endovascular cooling before reperfusion in patients with ST-elevation myocardial infarction. Circ Cardiovasc Interv 2010;3:400-407.
105. Munk K, Andersen NH, Schmidt MR, Nielsen SS, Terkelsen CJ, Sloth E, Botker HE, Nielsen TT, Poulsen SH. Remote ischemic conditioning in patients with myocardial infarction treated with primary angioplasty: impact on left ventricular function assessed by comprehensive echocardiography and gated singlephoton emission CT. Circ Cardiovasc Imaging 2010;3:656-662.
106. Rentoukas I, Giannopoulos G, Kaoukis A, Kossyvakis C, Raisakis K, Driva M, Panagopoulou V, Tsarouchas K, Vavetsi S, Pyrgakis V, Deftereos S. Cardioprotective role of remote ischemic periconditioning in primary percutaneous coronary intervention: enhancement by opioid action. JACC Cardiovasc Interv 2010; 3:49-55.
107. Mewton N, Croisille P, Gahide G, Rioufol G, Bonnefoy E, Sanchez I, Cung TT, Sportouch C, Angoulvant D, Finet G, Andre-Fouet X, Derumeaux G, Piot C, Vernhet H, Revel D, Ovize M. Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction. J Am Coll Cardiol 2010;55: 1200-1205.